Neuroimaging and neurophysiologic biomarkers for diagnosis and prognosis of depressive disorders, bipolar disorder, anxiety disorders, obsessive compulsive disorder, posttraumatic stress disorder, and substance use disorder: an evidence map - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Neuroimaging and Neurophysiological Markers for the Diagnosis and Prognosis of Mood Disorders, Anxiety Disorders, Obsessive-Compulsive Disorder, PTSD, and Substance Use Disorders: A Comprehensive Evidence Review

  • By

  • Catherine Sowerby

  • Adrienne Landsteiner

  • Kristen Ullman

  • Maylen Anthony

  • Caleb Kalinowski

  • Michele R. Spoont

  • Scott Sponheim

  • Kelvin Lim

  • Jose V. Pardo

  • Timothy J. Wilt

  • Wei Duan-Porter

  • May 6, 2026

Share

Original Source(s)

Neuroimaging and neurophysiologic biomarkers for diagnosis and prognosis of depressive disorders, bipolar disorder, anxiety disorders, obsessive compulsive disorder, posttraumatic stress disorder, and substance use disorder: an evidence map

  • by Catherine Sowerby, Adrienne Landsteiner, Kristen Ullman, Maylen Anthony, Caleb Kalinowski, Michele R. Spoont, Scott Sponheim, Kelvin Lim, Jose V. Pardo, Timothy J. Wilt, Wei Duan-Porter

  • May 6, 2026

Related Content

ADHD Stimulant Misuse Under Review

High-frequency misuse remains associated with polysubstance use, while no studies evaluated long-term physical health outcomes.

GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks

Editorial: Emerging treatment approaches for substance use disorders